Senology Newsletter

Senology.org - Newsletter

International Senologic and Oncologic Scientific Community (ISOSC)

"Connecting specialists worldwide"

Editor-in-Chief: Gian Paolo Andreoletti, MD

Subscribe Unsubscribe Contact Back Issues

Connecting Specialists Worldwide

SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US!

Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates

Literature Selection

Comment

"Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice", Franck Bonnetain, Biostatistics and Epidemiology Unit, Centre Georges Francois Leclerc (CGFL), Dijon, France

"Our study, with a median follow-up of 11 years, confirms that, for patients with primary operable non-metastatic breast cancer, neoadjuvant chemotherapy failed to improve overall survival. Then added value of neoadjuvant strategy for patient's clinical benefit remains uncertain without demonstrating improvement regarding health related quality of life. Furthermore, we found no difference in the final mastectomy rate between the treatment groups. Of note, it is important to underline that these results are based on an historical cohort. Such bias is inherent to long-term endpoint studies. Never mind our results underline that clinicians should pay caution against the use of neoadjuvant chemotherapy in an unselected population. Then we suggest that the use of neoadjuvant therapy in clinical practice should be carefully discussed before implementation to take into accounts the benefits and risks for the patient. Quality of life could be the cornerstone of this discussion."
(Comment on: Le Ray I et al.: "Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11years using propensity score matching", Eur J Cancer. 2012 Apr 16. [Epub ahead of print)
Share your opinion on LinkedIn®

Calendar of Events

Literature Selection

Fragments of History

Wilhelm Conrad Röntgen (Remscheid, Germany, 1845 – 1923): "On a new kind of rays", Science 1896 Feb 14;3(59):227-31

Discussion

""Benefit from adjuvant postoperative radiochemotherapy for curatively resected gastric cancer with primaries T3 or greater and/or positive nodes" - Share your opinion on LinkedIn®

Literature Selection

Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation.

TalkAboutHealth Q&A of the month

"When would you recommend the TDAP (thoracodorsal artery perforator) flap breast reconstruction and are there any advantages of this procedure?"

"There are several ways to borrow living tissue from the patient’s own body to replace the breast after mastectomy. Tissue is most commonly taken from the abdomen (TRAM, DIEP, SIEA) because there is commonly enough tissue there to make one or two breasts. Tissue can also be used from the buttocks, hips thighs and trunk. When tissue is taken from the trunk or side next to the breast we call it a lateral thoracic flap. The TDAP is one example. TDAP stands for Thoracodorsal Artery Perforator Flap. This is a local flap, meaning that it comes from near the area of the defect (breast). The skin and fat is harvested in one elliptical piece that is still connected to a tiny blood vessel that supplies it. This tissue is then moved over into the defect to either create a new breast or to correct a lumpectomy defect. TDAPs (and other lateral thoracic flaps) are used when there is enough volume of extra tissue at the donor area (the lateral thorax) to correct the defect caused by breast cancer surgery. Usually there is not enough extra tissue there to make a whole breast, so these procedures are most commonly used for partial breast reconstruction. The advantages of the lateral thoracic flaps are:1. Short hospital stay (24 hours). 2. Low failure rate 3. Favorable scar within the bra line. 4. Gets rid of unwanted extra tissue under the arm. "
(Answer by Joshua Levine , The New York Center for the Advancement of Breast Reconstruction, New York, NY, USA)

Stay informed....

Recent Advances in Clinical Medicine

Becattini C et al.: "Aspirin for preventing the recurrence of venous thromboembolism ", N Engl J Med. 2012 May 24;366(21):1959-67

www.senology.org